

# PRODUCT INFORMATION



## C-DMG-mPEG(2000)

Item No. 37149

**Formal Name:**  $\alpha$ -[3-[[[2,3-bis[(1-oxotetradecyl)oxy]propoxy]carbonyl]amino]propyl]- $\omega$ -methoxy-poly(oxy-1,2-ethanediyl)

**Synonyms:** PEG<sub>2000</sub>-C-DMG, Polyethylene Glycol-2000-C-DMG


**MF:**  $(C_2H_4O)_n C_{36}H_{69}NO_7$

**Purity:**  $\geq 95\%$

**Supplied as:** A solid

**Storage:**  $-20^\circ\text{C}$

**Stability:**  $\geq 4$  years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

C-DMG-mPEG(2000) is supplied as a solid. A stock solution may be made by dissolving the C-DMG-mPEG(2000) in the solvent of choice, which should be purged with an inert gas. C-DMG-mPEG(2000) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of C-DMG-mPEG(2000) in ethanol is approximately 10 mg/ml and approximately 25 mg/ml in DMSO and DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of C-DMG-mPEG(2000) can be prepared by directly dissolving the solid in aqueous buffers. The solubility of C-DMG-mPEG(2000) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

C-DMG-mPEG(2000) is a PEGylated derivative of 1,2-dimyristoyl-*sn*-glycerol (1,2-DMG; Item No. 15077).<sup>1</sup> It has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs) for the delivery of siRNA. LNPs containing C-DMG-mPEG(2000) and encapsulating siRNA targeting the genes encoding programmed cell death protein ligand 1 (PD-L1) and PD-L2 decrease PD-L1 and PD-L2 levels in monocyte-derived dendritic cells. Formulations containing C-DMG-mPEG(2000) have been used in the development of LNPs for the delivery of siRNA-based vaccines.

### Reference

1. Hobo, W., Novobrantseva, T., Fredrix, H., et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. *Cancer Immunol. Immunother.* **62**(2), 285-297 (2013).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/11/2025

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)